Immunovant (IMVT) CLO Van Tuyl Christopher Sells $93K of Stock

Van Tuyl Christopher, Chief Legal Officer of Immunovant, Inc. (NasdaqGS: IMVT), recently sold 2,634 shares of the company. The shares were sold at an average price of $35.39, resulting in a total transaction value of $93,217.26 on June 18, 2026. This transaction was not part of a pre-arranged trading plan.

Other Institutional Activity in Immunovant, Inc.

Several institutional investors have also been active in Immunovant, Inc. FMR LLC trimmed its holdings by 42,866 shares, bringing its total to 16,947,888 shares valued at approximately $420.99 million, a 0.3% decrease. Meanwhile, BlackRock, Inc. increased its position by 516,281 shares to a total of 6,574,497 shares worth about $163.31 million, marking an 8.5% increase. State Street Corp significantly boosted its stake by 751,003 shares, ending with 4,537,929 shares valued at $112.72 million, reflecting a 19.8% increase. TCG Crossover Management, LLC made a substantial addition of 2,797,055 shares, increasing its holdings by 168.4% to 4,457,988 shares valued at $110.74 million.

Immunovant, Inc. Stock Up 3.1%

Shares of Immunovant, Inc. traded near $38.10 on Tuesday. The company, with a market cap of approximately $7.82 billion, operates in the biotechnology industry. Immunovant has a forward P/E ratio of -15.64 and a beta of 0.79, indicating lower volatility compared to the market. The stock's 52-week range is between $14.32 and $38.74, with a 50-day moving average of $29.94 and a 200-day moving average of $24.73. The company maintains a strong financial position, with a current ratio of 9.09 and a very low debt-to-equity ratio of 0.008.

Analysts Set New Price Targets

Analysts have been actively updating their price targets for Immunovant, Inc. On May 26, 2026, Guggenheim maintained its 'buy' rating with a target price of $62.00. Truist Securities kept a 'hold' rating with a $30.00 target on May 22, 2026. B of A Securities also maintained a 'buy' rating, setting a target price of $43.00 on May 21, 2026. The consensus among analysts is a 'buy' rating, with an average target price of $45.76 among 17 opinions.

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage biotechnology company based in Durham, North Carolina. It focuses on developing targeted therapies to address autoimmune diseases. The company's lead product, IMVT-1402, is a monoclonal antibody designed to inhibit a specific receptor involved in various autoimmune conditions, including Graves' disease and rheumatoid arthritis. Founded in 2018, Immunovant operates as a subsidiary of Roivant Sciences Ltd.

Bottom Line

Immunovant, Inc. is on the radar of investors and analysts alike. With insider sales like that of Van Tuyl Christopher, market participants keep a close watch on such moves as part of broader investment strategies. Institutional activity and analyst ratings provide a snapshot of sentiment around this biotech firm. As always, 13F filings are backward-looking and do not necessarily reflect current holdings.